More than $5.5 million of CIHR funding awarded to NMD4C members to strengthen neuromuscular research capacity in Canada
Congratulations to the recipients of the Fall 2022 CIHR funded project grant competition! Seven projects were awarded (>5.5M) to NMD4C members to advance neuromuscular research in Canada: Drs. Rashmi Kothary and Cynthia Gagnon (steering committee members); Dr. Bernard Brais (investigator); Drs. Elise Duchesne (2 projects funded) and Gerald Pfeffer (working group members); and Drs. Yan Burelle, Nicolas Dumont (2 projects funded), Penney Gilbert, Luc Hébert, Mireille Khacho, Keir Menzies, Louise Moyle, and Toshifumi Yokota (members). Of note, 6/7 of the funded projects were awarded to early-career researchers (Drs. Nicolas Dumont, Elise Duchesne, Mireille Khacho, and Louise Moyle). Further information on the funding recipients can be found below.
Project Title: Extra-neuronal contribution to spinal muscular atrophy disease pathogenesis ($818,550).
Principal Investigator: Dr. Rashmi Kothary; Ottawa Hospital Research Institute
Project Title: Regulation of satellite stem cell fate by LINC complex proteins ($1,071,000).
Principal Investigator: Dr. Penney Gilbert; University of Toronto
Co-Investigators: Drs. Louise Moyle and Aaron Wheeler
Project Title: Therapeutic potential of bioactive lipids as anti-fibrotic therapy for muscle regeneration and dystrophies ($757,350).
Principal Investigator: Dr. Nicolas Dumont; Centre hospitalier universitaire Sainte-Justine (Montréal, Québec)
Project Title: Targeting defective cells to restore myogenesis and muscle function in myotonic dystrophy type 1 ($761,175).
Principal Investigators: Drs. Nicolas Dumont and Elise Duchesne; Centre hospitalier universitaire Sainte-Justine (Montréal, Québec)
Project Title: IMPACT, a supervised rehabilitation program for spastic ataxias: A rater-blinded, randomized controlled trial ($638,776).
Principal Investigators: Drs. Elise Duchesne, Mylene Aubertin, Bernard Brais, and Cynthia Gagnon; Université du Québec à Chicoutimi
Co-Investigators: Drs. Rubens da Silva, Raquel Fonseca, Luc Hébert, Gerald Pfeffer
Project Title: Mitochondrial Quality Control in Muscle Stem Cells: A Determinant of Cell Fate Decision and Tissue Repair Capacity ($692,325).
Principal Investigator: Dr. Yan Burelle; University of Ottawa
Co-Investigators: Drs. Mireille Khacho, Keir Menzies
Project Title: Neutrophil Responses in Doxorubicin-Induced Myopathy ($879,750).
Principal Investigator: Javier Clemente-Casares; University of Alberta
Co-Investigators: Gavin Oudit, Toshifumi Yokota
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.